Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.59 |
| ▸ | TDO2 | P48775 | 1/20 | 0.59 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719669 | 0.79 | IDO1 (0.74) | IDO1TDO2TBXAS1QPCTQPCTL | |
| SCHEMBL18378854 | 0.74 | IDO1 (1.00) | IDO1TDO2NAMPTTBXAS1POLB | |
| SCHEMBL2880191 | 0.73 | LMNA (0.54) | BRD9NAMPTMETAP1BRD4RXFP1 | |
| SCHEMBL15883630 | 0.73 | NPC1 (0.44) | IDO1BRD9BRD4GPR139LMNA | |
| SCHEMBL30680957 | 0.73 | BRD9 (0.45) | IDO1BRD9METAP1BRD4GPR139 | |
| SCHEMBL21436566 | 0.72 | EPHB3 (0.54) | IDO1BRD9LMNA | |
| SCHEMBL2170782 | 0.71 | POLB (0.43) | IDO1BRD9METAP1BRD4GPR139 | |
| SCHEMBL20697350 | 0.71 | ELANE (0.47) | BRD9METAP1BRD4GPR139RXFP1 | |
| SCHEMBL16691108 | 0.70 | CYP17A1 (0.47) | IDO1NAMPTTBXAS1CYP17A1 | |
| SCHEMBL18380888 | 0.70 | THRA (0.40) | BRD9METAP1BRD4GPR139RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4069694-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | Storm Therapeutics Ltd (GB) | 2022-10-12 | — | — | EP | disclosed |
| CN-115151540-A | Polyheterocyclic compounds as METTL3 inhibitors | 风暴治疗有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885BRD9 2857/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885BRD9 2857/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885BRD9 2857/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885BRD9 2857/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885BRD9 2857/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | IDO1 2631/4885TDO2 3302/4885BRD9 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.